Enovis Co. (NYSE:ENOV) Shares Sold by Cove Street Capital LLC

Cove Street Capital LLC cut its position in Enovis Co. (NYSE:ENOV) by 23.4% during the 4th quarter, HoldingsChannel reports. The firm owned 42,893 shares of the company’s stock after selling 13,070 shares during the quarter. Enovis makes up about 2.2% of Cove Street Capital LLC’s investment portfolio, making the stock its 18th largest position. Cove Street Capital LLC’s holdings in Enovis were worth $1,881,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Confluence Investment Management LLC bought a new position in Enovis in the 4th quarter worth approximately $3,494,000. Geode Capital Management LLC increased its holdings in shares of Enovis by 9.5% during the third quarter. Geode Capital Management LLC now owns 921,437 shares of the company’s stock valued at $39,678,000 after purchasing an additional 80,165 shares during the period. UMB Bank n.a. raised its stake in shares of Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after purchasing an additional 437 shares in the last quarter. Jane Street Group LLC lifted its holdings in Enovis by 247.6% in the third quarter. Jane Street Group LLC now owns 106,684 shares of the company’s stock worth $4,593,000 after purchasing an additional 75,988 shares during the period. Finally, FMR LLC grew its position in Enovis by 20.5% in the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after buying an additional 484 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Trading Down 2.9 %

Shares of Enovis stock opened at $37.74 on Friday. The business has a fifty day simple moving average of $42.06 and a 200-day simple moving average of $43.35. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -17.23 and a beta of 2.05. Enovis Co. has a fifty-two week low of $35.14 and a fifty-two week high of $62.79. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $560.98 million for the quarter, compared to analysts’ expectations of $555.14 million. On average, equities analysts forecast that Enovis Co. will post 2.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC dropped their price target on shares of Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.